Implied Volatility Surging for Urogen Pharma Stock Options
Implied volatility for Urogen Pharma Ltd. (URGN) stock options is surging, particularly for the November 20, 2026 $15.00 Put, indicating expectations of significant price movement. Analysts currently rate URGN as a Zacks Rank #3 (Hold), with recent upward revisions to earnings estimates suggesting a potential trading opportunity for options traders. This high implied volatility could attract seasoned traders looking to sell premium and capitalize on time decay.
UroGen Pharma Ltd (UR8.SG) Seasonal returns chart
The article provides a seasonal returns chart for UroGen Pharma Ltd (UR8.SG), displaying its average monthly price return from 2018 to 2026. As of the stated time, the stock is trading at 26.11 EUR, up 2.15%.
Toronto-Dominion Bank and TD Securities report 2.89 million shares in UroGen Pharma (URGN).
The Toronto-Dominion Bank and TD Securities Inc. have jointly reported beneficial ownership of 2,886,236 ordinary shares, or 5.9% of UroGen Pharma Ltd. (URGN) as of September 30, 2026. The Toronto-Dominion Bank holds sole voting and dispositive power over 2,770,530 shares (5.7%), while TD Securities Inc. holds 115,706 shares (0.2%). TD Bank disclaims ownership of TD Securities' shares except to the extent of its pecuniary interest.
UroGen Pharma Ltd. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
UroGen Pharma Ltd. (NASDAQ:URGN) shares dropped 24% after reporting a surprise statutory loss of US$0.03 per share on revenues of US$89m, despite analysts expecting a profit. Despite the loss, analysts slightly increased revenue forecasts for 2027 to US$539.7m, representing a 116% increase, and maintained earnings per share estimates at US$2.76, while also raising the consensus price target by 5.9% to US$61.71. The company is expected to significantly accelerate growth, with forecast annualized growth of 85% to the end of 2027, outpacing its historical 28% annual growth and the industry's projected 21% annual revenue growth.
Earnings call transcript: UroGen Pharma tops EPS view in Q3 2026, shares slide
UroGen Pharma reported a narrower-than-expected loss in Q3 2026, with EPS of -$0.03 against an expected -$0.0488, driven by strong demand for its bladder-cancer drug ZUSDURI. However, shares slid over 12% in premarket trading due to a slight revenue miss at $89 million (vs. $90.58 million forecast) and concerns about increased spending and pressure on its older product, JELMYTO. The company expects to achieve profitability and positive cash flow in Q4 2026, and is advancing its pipeline with UGN-103 and UGN-501.
Urogen Pharma Q3 Earnings Call Highlights
Urogen Pharma reported strong third-quarter revenue of $89 million, more than triple the prior year, driven by the continued growth of ZUSDURI sales. The company narrowed its net loss significantly and expects to achieve profitability and positive cash flow in the fourth quarter of 2026. UroGen provided updated guidance for JELMYTO and outlined pipeline plans, including the FDA's acceptance of UGN-103's application with a decision goal date of June 14, 2027.
UroGen Pharma Q3 2026 Earnings Call Transcript
UroGen Pharma reported strong third-quarter results for 2026, with Zesturi net product revenue reaching $68 million, a 35% sequential increase, driven by greater physician adoption and repeat utilization for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. Jelmyto revenue was $21 million, impacted by a one-time adjustment and clinical trial competition. The company also announced the FDA acceptance of its NDA for UGN-103 with a PDUFA goal date of June 14, 2027, and a strategic collaboration with Intragel Therapeutics to develop new oncology products.
Form 10-Q UroGen Pharma Ltd. For: Sep 30
UroGen Pharma Ltd. filed its Form 10-Q for the quarter ended September 30, 2026, reporting a net loss of $1.462 million for the three months ended September 30, 2026, and $39.387 million for the nine months ended September 30, 2026. The company's revenue significantly increased due to the commercial launch of Zusduri, while research and development expenses also rose due to ongoing clinical trials and regulatory fees. UroGen Pharma continues to focus on commercializing Jelmyto and Zusduri and advancing its pipeline of urothelial and specialty cancer treatments.
UROGEN PHARMA ($URGN) Releases Q3 2026 Earnings
UROGEN PHARMA ($URGN) reported its Q3 2026 earnings, missing both earnings per share and revenue estimates. The company reported an EPS of -$0.03 against an estimate of $0.14, and revenue of $89 million, below the $91.7 million estimate. Insider trading activity showed sales by officers, while institutional investors had mixed activity, with some significantly adding and removing shares.
Form 8K Urogen Pharma Ltd For: 4 November By Investing.com
Urogen Pharma Ltd filed a Form 8K for November 4th, as reported by Investing.com. The article simply states the filing and provides current financial market data, including indices, commodities, bonds, and shares, along with popular news and market movers.
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
UroGen Pharma announced strong third-quarter 2026 financial results, with ZUSDURI revenue reaching $68.0 million, a 35% quarter-over-quarter increase. The company also reported the FDA's acceptance of its NDA for UGN-103, with a PDUFA goal date of June 14, 2027, and the first patient dosed in the UGN-501 Phase 1 trial. UroGen updated its full-year 2026 JELMYTO revenue guidance to approximately $90 million and maintained its operating expense guidance of $260 million to $270 million.
UroGen Pharma Q3FY26 Results: Revenue surges 224% YoY to $89 million
UroGen Pharma reported a 224% year-over-year revenue surge to $89 million in Q3FY26, primarily driven by $68 million in net product revenue from the commercial launch of Zesturi. The company significantly narrowed its net loss to $1.5 million and anticipates achieving profitability and positive cash flow in Q4FY26. While Zesturi showed strong sequential growth with increasing physician adoption, Jelmyto faced competitive headwinds and a slight revenue decline, prompting an updated full-year guidance for the product.
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
UroGen Pharma (URGN) announced it will present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 11:30 AM ET. The presentation will feature a fireside chat and one-on-one investor meetings in Boston. A webcast of the event will be available on UroGen's corporate website under "Events & Presentations," with a replay accessible for approximately 90 days.
UroGen Pharma Share News - Latest Updates, Live News & More
This article provides the latest news and updates regarding UroGen Pharma, including its upcoming Q3 FY26 earnings report, analyst ratings, and recent deals. It highlights key financial performance metrics and significant company announcements, offering a snapshot of the company's recent activities and market sentiment.
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
UroGen Pharma Ltd. (Nasdaq: URGN) announced that its management will present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference, scheduled for November 9-11, 2026. The presentation will be a fireside chat on November 10, 2026, at 11:30 AM ET, and will also involve 1x1 investor meetings in Boston, MA. A webcast of the conference will be available on UroGen’s corporate website.
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
UroGen Pharma Ltd. announced that its management will present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 11:30 AM ET. The presentation will feature a fireside chat and 1x1 investor meetings in Boston, MA, with a webcast available on UroGen’s corporate website. UroGen is a biotechnology company focused on developing innovative treatments for urothelial and specialty cancers, utilizing its proprietary RTGel sustained-release hydrogel platform.
UroGen Pharma Stock In Focus As First Patient Is Dosed In Bladder Cancer Trial
UroGen Pharma announced that the first patient has been dosed in its Phase 1 trial of UGN-501 for recurrent non-muscle invasive bladder cancer. This milestone is an additional clinical development for the company, although the immediate focus remains on ZUSDURI's commercialization and managing operating expenses. Analysts project significant revenue and earnings growth for UroGen Pharma by 2029, with some optimistic models foreseeing even higher growth based on UGN-501's potential.
UroGen doses first patient in UGN-501 bladder cancer trial By Investing.com
UroGen Pharma Ltd. has announced that the first patient has been dosed with UGN-501, an investigational oncolytic virus, in a Phase 1 clinical trial for non-muscle invasive bladder cancer. The trial will assess the safety, tolerability, and pharmacokinetics of UGN-501, administered intravesically, in adults with recurrent non-muscle invasive bladder cancer. This marks a significant step in moving the therapy from nonclinical research to clinical evaluation, with parallel studies exploring a formulation using the company's RTGel technology.
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen Pharma has dosed the first patient in its Phase 1 trial for UGN-501, an investigational next-generation oncolytic virus designed to treat recurrent non-muscle invasive bladder cancer (NMIBC). This open-label, dose-escalation study will assess the safety, tolerability, and pharmacokinetics of UGN-501 administered directly into the bladder to determine a recommended Phase 2 dose. The current trial uses an aqueous formulation of UGN-501, while UroGen is also exploring an RTGel-formulated version in parallel nonclinical studies.
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. announced that the first patient has been dosed in a Phase 1 clinical trial for UGN-501, an investigational next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial will assess the safety, tolerability, and feasibility of intravesical administration of UGN-501, which is designed to combine direct tumor cell destruction with anti-tumor immune activation. This milestone advances UroGen's goal of expanding treatment options for bladder cancer patients, particularly those with recurrent NMIBC.
UroGen Pharma (URGN) Following Durable JELMYTO Data Is Its Bladder Cancer Story Fully Valued
UroGen Pharma (URGN) is gaining investor attention after releasing five-year follow-up data for JELMYTO, which demonstrated durable responses in low-grade upper tract urothelial cancer. Despite recent share price pullbacks, the stock has seen a significant year-to-date increase, leading to questions about whether its clinical advancements, including progress with UGN-103, are fully reflected in its current valuation. Analysts generally view UroGen Pharma as undervalued, but its high price-to-sales ratio compared to peers suggests potential valuation risks if operating losses continue or product adoption falls short of expectations.
UroGen Pharma (URGN) Following Durable JELMYTO Data Is Its Bladder Cancer Story Fully Valued
UroGen Pharma is gaining attention after releasing positive five-year follow-up data for JELMYTO, demonstrating durable responses in low-grade upper tract urothelial cancer. While its share price has seen recent declines over the past 30 and 90 days, it boasts a significant year-to-date and 3-year return. The article discusses whether the company's clinical story, including JELMYTO's data and UGN-103's NDA progress, is fully reflected in its current valuation, contrasting analyst fair value targets with its P/S ratio relative to peers.
Urogen Pharma Stock Price Forecast. Should You Buy URGN?
StockInvest.us rates UroGen Pharma Ltd (URGN) as a "Sell Candidate" with a technical score of -2.96 based on market data through November 3, 2026. The stock has experienced a 10.09% decline since its sell signal on October 13, 2026, and is forecasted to fall an additional 28.32% over the next three months. The analysis indicates negative signals and advises against buying the stock.
UroGen Pharma Ltd. (URGN) Seasonal returns chart
This article provides a seasonality chart for UroGen Pharma Ltd. (URGN), showing the average monthly price return from 2017 to 2026. It highlights key financial information such as the stock's current price, daily change, and upcoming earnings call. The chart helps investors understand historical seasonal trends for the stock.
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma announced final results from its Olympus five-year follow-up study for JELMYTO, demonstrating durable responses in adult patients with low-grade upper tract urothelial cancer. Among 20 complete responders in the long-term follow-up group, 75% remained event-free as of March 2025, with no progression to high-grade disease observed. The study reinforces JELMYTO's effectiveness as a kidney-sparing treatment option.
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd. announced the publication of final results from its Olympus long-term follow-up study, demonstrating the durable response of JELMYTO in treating low-grade upper tract urothelial cancer (LG-UTUC). The five-year data, published in Therapeutic Advances in Urology, showed sustained disease control with a median duration of response of 47.8 months among patients who achieved a complete response, with no progression to high-grade disease observed during extended follow-up. These findings support JELMYTO as a kidney-sparing treatment option offering long-lasting results for patients.
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
UroGen Pharma Ltd. announced it will report its third-quarter 2026 financial results on Wednesday, November 4th, 2026, before the stock market opens. This will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time, accessible via their Investor Relations website. The company specializes in developing innovative solutions for urothelial and specialty cancers, utilizing its RTGel® sustained-release hydrogel technology.
UroGen Pharma Ltd. Estimates – NASDAQ:URGN
This page provides financial data and analyst estimates for UroGen Pharma Ltd. (NASDAQ: URGN), accessible through TradingView. Users can explore reported financial data, compare actual results with estimates, and visualize trends over time across income statements, balance sheets, and cash flow statements. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Is FDA Filing Acceptance Altering The Investment Case For UroGen Pharma (URGN)?
UroGen Pharma announced the FDA's acceptance of its New Drug Application for UGN-103, targeting recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, with a PDUFA date of June 14, 2027. While this strengthens the long-term investment narrative by expanding their RTGel platform, the company still faces significant near-term financial challenges including heavy losses and a short cash runway. Investors are focused on the commercial success of existing therapies and balance sheet management to bridge the gap until UGN-103 can contribute to revenue.
UroGen Pharma Ltd. (URGN) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on UroGen Pharma Ltd. (URGN) stock, including its current price, historical data, financial performance, and analyst ratings. The company, a biotechnology firm, specializes in developing and commercializing solutions for urothelial and specialty cancers, featuring products like Jelmyto and pipeline candidates in various clinical trial phases. Key financial metrics, revenue trends, and a corporate overview highlight its operations in Princeton, New Jersey.
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $58
Guggenheim has reiterated its Buy rating for UroGen Pharma Ltd (URGN.US) and maintained its target price at $58. This indicates the firm's continued positive outlook on the company's stock performance.
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $58
Guggenheim has reiterated its Buy rating on UroGen Pharma Ltd (URGN.US) and maintained its target price at $58. This indicates a continued positive outlook from the firm regarding UroGen Pharma's stock performance.
UroGen Pharma (URGN) Wins FDA Filing Acceptance, Is The Stock Still Cheap?
UroGen Pharma (URGN) recently received FDA acceptance for its New Drug Application for UGN-103, an investigational bladder cancer treatment, with a decision date set for June 14, 2027. Despite a recent short-term stock pullback, URGN shares are up significantly year-to-date and over the past year. Analysts view the stock as undervalued, with a fair value estimate of $60, driven by the potential of its ZUSDURI product and broader urothelial cancer platform.
FDA accepts UGN-103 filing and UroGen Pharma stock trades at EUR 30.50
The FDA has accepted UroGen Pharma's application for UGN-103, an investigational bladder-cancer treatment, with a target action date of June 14, 2027. UroGen Pharma stock was trading at EUR 30.50 at Lang & Schwarz. The application is supported by positive results from the UTOPIA trial, which reported a 77.80 percent complete response rate at three months.
URGN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $75
UroGen Pharma (URGN) received a reiterated 'Buy' rating from HC Wainwright & Co., with its price target maintained at $75. Despite this positive analyst sentiment and strong growth potential (GF Score 73/100), GuruFocus indicates the stock is currently overvalued by 9.5% relative to its intrinsic GF Value of $30.70. Investors should also note significant insider sell activity totaling over $3 million in the last three months.
UroGen Pharma Announces FDA Acceptance of NDA for UGN-103 for Recurrent Bladder Cancer
UroGen Pharma announced that the FDA has accepted its New Drug Application (NDA) for UGN-103, a treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The FDA has set a target action date of June 14, 2027. UGN-103, utilizing UroGen's RTGel® technology, showed a 77.8% complete response rate in the Phase 3 UTOPIA trial, building on the success of their previously approved drug, ZUSDURI.
A bladder cancer drug candidate had a 77.8% complete response rate at three months.
UroGen Pharma announced that the FDA has accepted its New Drug Application (NDA) for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The application is supported by data from the Phase 3 UTOPIA trial, which showed a 77.8% complete response rate at three months and an estimated 94.5% event-free probability at six months for responders. The FDA target action date is June 14, 2027.
UroGen Announces FDA Acceptance of the New Drug Application
UroGen Pharma Ltd. announced that the FDA has accepted its New Drug Application (NDA) for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The FDA has set a PDUFA target action date of June 14, 2027. This acceptance is supported by positive clinical data from the Phase 3 UTOPIA trial, showing a 77.8% complete response rate at three months.
UroGen appoints Liz Barrett as CEO ahead of UroGen Pharma stock results
UroGen Pharma has appointed Liz Barrett as its new CEO, a move that comes as the company prepares to report its third-quarter 2026 results on November 5. The appointment is expected to add commercial weight, given Barrett's background in oncology at Novartis, aligning with UroGen's urothelial cancer pipeline. The company reported strong second-quarter revenue growth and anticipates higher revenue and positive earnings per share for the third quarter.
MarketBeat cites USD 52.38 target for UroGen Pharma stock
MarketBeat has set a USD 52.38 average price target for UroGen Pharma (URGN) following strong second-quarter 2026 revenue of USD 72.5 million, significantly up from the previous year. This target is based on ten brokerage ratings and comes ahead of the anticipated third-quarter results on November 5, 2026. The company's revenue growth is primarily driven by its product ZUSDURI, with JELMYTO also contributing to sales.
(URGN) Risk Channels and Responsive Allocation
This article analyzes Urogen Pharma Ltd. (NASDAQ: URGN), highlighting a mixed sentiment outlook with weak near and mid-term signals but a strong long-term positive outlook. It identifies an exceptional 73.6:1 risk-reward setup targeting a 21.3% gain against a 0.3% risk. The analysis provides AI-generated institutional trading strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
UroGen Pharma Ltd. (URGN) options chain
This article provides detailed options chain data for UroGen Pharma Ltd. (URGN), including calls and puts with various strike prices and expiration dates. The data, delayed by 15 minutes, shows last trade dates, prices, bid/ask spreads, changes, volume, open interest, and implied volatility for options expiring on January 15, 2027. UroGen Pharma's stock closed at $36.58, down 4.39%, on October 14.
Form 4 Urogen Pharma Ltd For: 9 October By Investing.com
This article announces the filing of a Form 4 for Urogen Pharma Ltd on October 9. It is a brief, unelaborated notice published by Investing.com, likely indicating an insider transaction or change in ownership that companies are required to disclose. The piece primarily serves as an alert for interested investors.
UroGen Pharma CFO Chris Degnan sells $80,791 in shares By Investing.com
UroGen Pharma CFO Chris Degnan sold 2,202 ordinary shares for $80,791 on October 8, 2026, to cover withholding taxes from restricted stock unit settlements. Concurrently, he acquired 4,483 shares through RSU settlement, bringing his direct holdings to 4,561 ordinary shares and 4,484 RSUs. This transaction follows a significant 125% stock return over the past year, despite a recent 11% decline, and occurs amidst positive company news regarding strong Q2 2026 revenue and FDA application for UGN-103.
Form 4 Urogen Pharma Ltd For: 9 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Urogen Pharma Ltd on October 9. Form 4 filings are typically used to report changes in beneficial ownership of securities by company insiders. The brief news item includes the company's stock symbol URGN and notes a slight decrease in its share price.
Form 4 Urogen Pharma Ltd For: 9 October
This article announces the filing of Form 4 for Urogen Pharma Ltd on October 9. The content is very brief, serving primarily as a notification of the filing. It includes the stock symbol URGN and a minor price performance note.
Form 144 UroGen Pharma Ltd. For: 9 October By Investing.com
This article announces the filing of Form 144 for UroGen Pharma Ltd. on October 9. Form 144 is a notice of the intent to sell restricted securities. The brief notice highlights UroGen Pharma Ltd. with its stock symbol URGN.
Form 144 UroGen Pharma Ltd. For: 9 October By Investing.com
This article briefly reports on the filing of Form 144 by UroGen Pharma Ltd. for October 9, 2026. The filing is presented without additional commentary or details regarding the nature of the transaction. The content primarily serves as a notification of the filing.
Form 144 UroGen Pharma Ltd. Filed by: Degnan Chris
Christopher Degnan, an officer of UroGen Pharma Ltd., has filed a Form 144 to sell 2,202 ordinary shares valued at approximately $89,621.40. These shares were acquired on October 8, 2026, upon the vesting of restricted stock units (RSUs) and are being sold to cover tax withholding obligations. Oppenheimer & Co. Inc. is the broker for this transaction, which is expected to occur around October 8, 2026, on the Nasdaq exchange.
To cover equity-award taxes, UroGen Pharma (URGN) officer proposes selling 2,202 shares.
UroGen Pharma Ltd. officer Christopher Degnan has proposed selling 2,202 ordinary shares, valued at approximately $89,621.40, to cover tax withholding obligations associated with the vesting of equity awards. The sale is slated for around October 8, 2026. This filing highlights the common practice of executives selling shares to manage tax liabilities from equity compensation.